“For the many people with [cystic fibrosis] living in poorer countries, Trikafta is simply unaffordable at current listed prices.” The letter said it costs Vertex as little as $6,000 to make ...

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

When I was first diagnosed with CF, I wasn’t supposed to live past the age of 8. Then Trikafta gave me the chance for a future I wasn’t prepared for. I’ve built a new life for myself and learned to ...

The approval of Trikafta will make “a novel treatment available to most cystic fibrosis patients, including adolescents, who previously had no options,” said acting FDA Commissioner Ned Sharpless.

When Liu and his team tested the machinery in airway cells taken from patients with CF, they found that it restored the function of ion channels to the same level as the leading combination therapy ...

The patients of cystic fibrosis (CF), their families, and public health experts are pinning their hopes on the expected outcome from the Karnataka High Court regarding availability of affordable ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

SAN DIEGO — In a cohort of nearly 300 pediatric patients with cystic fibrosis, food allergy was found in less than 4% of the population, which was a lower proportion than the general pediatric ...